A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Buprenorphine/samidorphan (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms FORWARD-4
- Sponsors Alkermes plc
- 11 May 2017 According to an Alkermes media release, pooled data from FORWARD-4 and FORWARD-5 will be presented at the Society of Biological Psychiatry (SOBP) Annual Meeting.
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2016 Primary endpoint (Change from baseline in the MRDRS score) has not been met, according to an Alkermes plc media release.